BiomX Inc., a publicly traded clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announced that it has entered into a definitive merger agreement with Adaptive Phage Therapeutics, Inc., a privately held clinical-stage company advancing therapies to treat multi-drug resistant infections. Concurrently with entering into the definitive merger agreement, BiomX entered into a definitive purchase agreement providing for the sale by BiomX of shares of newly created non-voting convertible preferred stock and warrants to purchase shares of BiomX common stock in a private placement to certain institutional accredited investors. The private placement is expected to result in gross proceeds to BiomX of $50 million. The proceeds from the private placement are expected to advance the combined company’s two lead product candidates through Phase 2 clinical readouts.

A WilmerHale team including Glenn Pollner and Leigh Krafchek is representing the placement agents, RBC Capital Markets and Laidlaw & Company (UK) Ltd., in the private placement.